Qu FJ, Wu S, Kong Y. Oral fruquintinib combined with tegafur-gimeracil-oteracil potassium for advanced colorectal cancer to obtain longer progression-free survival: A case report. World J Gastrointest Oncol 2023; 15(5): 902-910 [PMID: 37275454 DOI: 10.4251/wjgo.v15.i5.902]
Corresponding Author of This Article
Yan Kong, MD, Professor, Department of Oncology, Affiliated Dalian Third People’s Hospital of Dalian Medical University, No. 40 Qianshan Road, Dalian 116033, Liaoning Province, China. kongkongyan2022@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. May 15, 2023; 15(5): 902-910 Published online May 15, 2023. doi: 10.4251/wjgo.v15.i5.902
Oral fruquintinib combined with tegafur-gimeracil-oteracil potassium for advanced colorectal cancer to obtain longer progression-free survival: A case report
Fan-Jie Qu, Shuang Wu, Yan Kong
Fan-Jie Qu, Shuang Wu, Yan Kong, Department of Oncology, Affiliated Dalian Third People’s Hospital of Dalian Medical University, Dalian 116033, Liaoning Province, China
Author contributions: Qu FJ, Wu S, and Kong Y were responsible for collecting data, analyzing data, and writing the article; Kong Y was responsible for guiding the writing and participating in the revision of the article; All authors read and approved the final manuscript.
Informed consent statement: The patient provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare that there are no conflicts of interest regarding the publication of this paper.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yan Kong, MD, Professor, Department of Oncology, Affiliated Dalian Third People’s Hospital of Dalian Medical University, No. 40 Qianshan Road, Dalian 116033, Liaoning Province, China. kongkongyan2022@163.com
Received: January 26, 2023 Peer-review started: January 26, 2023 First decision: March 8, 2023 Revised: March 13, 2023 Accepted: April 7, 2023 Article in press: April 7, 2023 Published online: May 15, 2023 Processing time: 105 Days and 19.3 Hours
Core Tip
Core Tip: After the failure of second-line standard therapy, effective treatment options for metastatic colorectal cancer (CRC) are limited. Here, we describe a patient with CRC with multiple lung metastases. Disease progression occurred after oxaliplatin + 5-fluorouracil or capecitabine as first-line treatment and bevacizumab + irinotecan as second-line treatment. The patient received targeted therapy with fruquintinib and responded well for 12 mo. Progression-free survival was again achieved over 13.5 mo by continuing fruquintinib in combination with tegafur-gimeracil-oteracil potassium chemotherapy. This case detailed preliminary evidence showing that the combination of fruquintinib with tegafur-gimeracil-oteracil potassium resulted in longer progression-free survival in patients with CRC.
